Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Key Financial Performance
Cash Balance As of September 30, 2025, the cash balance was approximately $5.8 million.
Consolidated Operating Expenses For the 3 months ended September 30, 2025, operating expenses were approximately $1.5 million, down by approximately $1.4 million or 48% year-over-year from $2.9 million in the same period of 2024. The decrease was due to reductions in payroll, general and administrative expenses, and professional fees.
Payroll and Related Expenses Decreased by approximately $778,000 year-over-year due to lower headcount, reduced bonus accruals, and absence of prior year severance charges.
General and Administrative Expenses Declined by approximately $437,000 year-over-year, driven by lower clinical trial costs, a $218,000 R&D tax incentive credit from the Australian government, and reductions in supplies, insurance, and other operational costs.
Professional Fees Decreased by approximately $177,000 year-over-year, mainly due to reduced investor relations and contract labor expenses, partially offset by higher legal, tax audit, and financial services costs.
Operating Loss Decreased to $1.5 million for the quarter, compared to $2.8 million in the prior year period, reflecting a reduction in expenses and alignment with strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hemopurifier Oncology Trial: Progress in Australian oncology trial for Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 agents. Cohort 1 completed with no device-related complications. Advancing to Cohort 2 with two treatments in a week. Safety and exploratory efficacy data being collected.
Long COVID Research: Presented preclinical data on Hemopurifier's potential for Long COVID treatment. Studying extracellular vesicles' role in Long COVID and preparing a manuscript for publication.
Simplified Hemopurifier System: Signed agreement to study compatibility of Hemopurifier with a simplified system for oncology units, potentially reducing operational complexity.
Clinical Trial Expansion: Efforts to accelerate enrollment in Australian oncology trial include virtual investigator meetings, adding new sites, and clinical trial advertising.
Cost Reductions: Operating expenses reduced by 48% YoY to $1.5M due to lower headcount, reduced bonuses, and Australian R&D tax incentives.
Resource Alignment: Operating loss reduced to $1.5M from $2.8M YoY, reflecting alignment of resources with strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Australian Oncology Trial Enrollment: Challenges in accelerating participant enrollment for the Hemopurifier trial, requiring a multi-pronged strategy including virtual meetings, additional site identification, and clinical trial advertising.
Regulatory Approval Process: The need for extensive safety and efficacy trials, including a premarket approval study (PMA), to meet FDA and other regulatory requirements, which could delay product commercialization.
Long COVID Research: No approved treatment for Long COVID exists, and while the Hemopurifier shows potential, further research and validation are required, posing a challenge to market entry.
Operational Complexity: Current Hemopurifier operation requires a large double-lumen dialysis catheter, a complex dialysis machine, and specialized staff, limiting its usability in oncology units.
Financial Sustainability: Limited cash balance of $5.8 million as of September 30, 2025, with ongoing operating expenses, raising concerns about long-term financial sustainability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Australian oncology trial: The trial is advancing to the second cohort where participants will receive two Hemopurifier treatments during a 1-week treatment period. Efforts are being made to accelerate enrollment through virtual investigator meetings, adding new sites, and clinical trial advertising. The trial aims to determine the safety and efficacy of Hemopurifier treatments, with exploratory analyses to inform future efficacy and safety trials, including a premarket approval study required by the FDA and other regulatory agencies.
Preclinical R&D activities: Aethlon Medical is studying the cargo of extracellular vesicles removed from Long COVID patient samples and preparing a manuscript for publication. The company has signed a material transfer agreement to explore a simplified system for Hemopurifier treatments, which could enable treatments in oncology units in the future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:To what extent will potential participants in Cohort 2 understand the positive responses in Cohort 1?
A:The investigators were briefed on the observations from Cohort 1 during a virtual meeting, and they were provided guidance on how to explain the trial to patients. This ensures that participants understand the context and findings from Cohort 1.
Q:Is there any subsequent data from the Cohort 1 participants beyond the 7-day follow-up?
A:The observations were based on lab data up to 8 weeks, and no further EV or T cell data is expected. Clinical follow-up is ongoing but is not an endpoint of the trial.
Q:What should be expected from Cohort 2 in terms of dosage and safety findings?
A:Cohort 2 involves two treatments in a week (Monday and Friday). The main objective is to assess if participants can tolerate two treatments and to observe if EV decreases and T cell changes are more profound compared to Cohort 1.
Q:What is the company's focus regarding the Hemopurifier and other indications?
A:The company is focusing on Long COVID data and plans to submit it to a peer-reviewed journal. While monitoring other indications, they are prioritizing efforts based on resources and funding.
Q:Has the company considered government funding to optimize spending?
A:The company is open to government contracts if they align closely with their goals. However, current government contracts are less profitable due to overhead reductions, making them less appealing unless they directly support the company's objectives.
Q:Why is patient recruitment for Cohort 2 taking longer than expected?
A:Recruitment is challenging because the procedure involves a large catheter and blood filtration, which requires detailed explanation to patients. Additionally, the novel concept of EV removal in cancer and the time commitment for samples contribute to slower enrollment.
Q:Is the timeline for completing Cohort 2 by mid-2026 reasonable?
A:The company anticipates enrolling one patient per month, but factors like holidays in Australia may cause delays. They are implementing measures like digital marketing and adding more sites to accelerate enrollment.
Q:Does the current data support the hypothesis that the Hemopurifier can extend patient life or improve outcomes for immunotherapy patients?
A:The data from three patients shows directional changes in EV decreases and lymphocyte populations involved in tumor killing. While promising, more data is needed to confirm these findings.
Q:Were the lower EV levels observed in the Australian study stable over time?
A:EV levels decreased during treatment and rebounded over a couple of weeks, which was expected. Cohort 2 aims to determine if more frequent treatments can sustain lower EV levels for longer.
Q:Will Cohort 2 participants be followed for longer than 8 weeks?
A:No, the EV and T cell data collection for Cohort 2 will also be limited to 8 weeks post-treatment.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the statistical significance of the data from Cohort 1, emphasizing that it is an early safety and feasibility trial and refraining from commenting on clinical responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aethlon Medical
CD cell
CEO CFO
COVID infection
COVID vesicle
Conference
MTA
PD
RD
agency
blood
cancer metastasis
cargo vesicle
catheter
cell participant
cohort participant
concentration
count
decrease EVs
dialysis
effort
hour treatment
immunotherapy
investigator
laboratory
lectin
lumen
lymphocyte
magnitude
participant treatment
participant trial
ratio
regimen
subset EVs
system
treatment period
trial participant
unit
week treatment
AEMD Transcript
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Neutral6-10
Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Unknown2-12
The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Unknown11-12
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
Unknown8-13
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
AEMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
